DakoCytomation Offers New Diagnostic Option for Breast Cancer Patients in Europe

01-Jun-2004
Copenhagen, Denmark. DakoCytomation now offers the HER2 FISH pharmDx(TM) test for use as an aid in identifying European breast cancer patients eligible for Herceptin(TM) therapy. Herceptin(TM), marketed by Roche in Europe, is a targeted monoclonal antibody treatment for women with HER2-positive metastatic breast cancer. HER2 FISH pharmDx(TM) is a fluorescence in situ hybridization (FISH) assay designed to quantitatively determine HER2 gene amplification in breast cancer tissue. "We are pleased to offer a new tool to aid in assessing patients with metastatic breast cancer," said Jes ?stergaard, CEO of DakoCytomation. "This assay is a significant addition to our portfolio of pharmacodiagnostic products designed to help physicians identify the most appropriate targeted therapy." HER2 FISH pharmDx(TM), which is not available in the United States, will compliment DakoCytomation's HercepTest(TM) - the first clinical test to help assess candidates for a specific targeted therapy. HercepTest is a slide-based assay that demonstrates levels of HER2 protein overexpression in patient samples. The new highly sensitive HER2 FISH pharmDx(TM) assay will provide additional clarification and ensure the most appropriate use of Herceptin. DakoCytomation also recently received regulatory approval in both the United States and in Switzerland for use of its EGFR pharmDx(TM) kit as an aid in identifying colorectal cancer patients eligible for treatment with ERBITUX(TM) (cetuximab).

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances